SEC Form	4
----------	---

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number:	3235-0287							
Entire stand succession	hurdon							

Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person <sup>*</sup> MELLETT PAUL J		son*	2. Issuer Name and Ticker or Trading Symbol <u>ENANTA PHARMACEUTICALS INC</u> [ ENTA ]	(Check	ationship of Reporting Person(s) to Issuer < all applicable) Director 10% Owner Officer (give title Other (specify			
(Leet)	(First)	(Middle)		X	below)	below)		
	) (First) (Middle) ENANTA PHARMACEUTICALS, IN ARSENAL STREET		3. Date of Earliest Transaction (Month/Day/Year) 12/16/2019		Treasurer and CFO			
500 ARSENAL	STREET			<u> </u>				
(Street) WATERTOWN	МА	02472	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Line) X Form filed by One Reporting Pe Form filed by More than One R Person		eporting Person		
(City)	(State)	(Zip)						

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table 1 Nen Bernarie Coouncie Acquirea, Bioposed el, el Beneniany ennea											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)	
Common Stock	12/16/2019		М		2,625 <sup>(1)</sup>	A	(2)	51,219 <sup>(3)</sup>	D		
Common Stock	12/16/2019		F		1,165(4)	D	\$63.88	50,054	D		
Common Stock	01/02/2020		<b>S</b> <sup>(5)</sup>		9,279	D	\$60.8192(6)	40,775	D		
Common Stock	01/02/2020		<b>S</b> <sup>(5)</sup>		721	D	\$61.6619(7)	40,054	D		

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deri Sec Acq (A) o Disp of (I (Ins	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(2)	12/16/2019		М			2,625	(8)	(8)	Common Stock	2,625	\$ <mark>0</mark>	2,625 <sup>(8)</sup>	D	

### Explanation of Responses:

1. Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2019. The settlement and issuance of the shares was subject to continued employment and occurred on December 16, 2019.

2. Restricted stock units convert into ENTA common stock on a one-for-one basis.

3. Since the date of the reporting person's last ownership report, he transferred 48,594 shares of ENTA common stock and 5,250 restricted stock units (which convert into ENTA common stock on a one-for-one basis) to his ex-wife pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-wife.

4. Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award.

5. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in November 2019.

6. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$60.39 to \$61.31, inclusive.

7. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$60.40 to \$62.09, inclusive.

8. On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units vested on November 18, 2019 and the remainder will vest on November 18, 2020, subject to the reporting person's continued employment. As noted in footnote 3 above, 5,250 of the restricted stock units were transferred to the reporting person's ex-wife pursuant to a domestic relations order and the reporting person no longer reports as beneficially owned any securities owned by his ex-wife.

### Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 6 and 7 above.

<u>/s/ Paul J. Mellett</u> \*\* Signature of Reporting Person

Date

01/06/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.